Evaluating Fluoxetine’s Growth-Inhibitory Impact on Clinical Isolates of Enteric Bacteria: Harnessing Repurposing Potential. (2023). Microbiological & Immunological Communications, 2(2), 89-96. https://doi.org/10.55627/mic.002.02.0454